Senseonics Holdings Inc (SENS)

[$Pistol Pete$]

$SENS Current Report Filing (8-k)

Source: Edgar (US Regulatory)


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 21, 2018

SENSEONICS HOLDINGS, INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware

001-37717

47-1210911
(State or Other
Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

20451 Seneca Meadows Parkway
Germantown, MD 20876-7005
(Address of Principal Executive Office) (Zip Code)

Registrant’s telephone number, including area code: [phone]

Not Applicable
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2 below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x





Item 7.01 Regulation FD Disclosure.

On June 21, 2018, Senseonics Holdings, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has approved its Pre-market Approval (“PMA”) application to market the Company’s Eversense® Continuous Glucose Monitoring (“CGM”) System. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not incorporated by reference into any of the Company’s filings under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

Item 8.01 Other Events.

On June 21, 2018, the Company announced that the FDA has approved its PMA application to market the Company’s Eversense® CGM System to people 18 years of age and older with diabetes in the United States for up to 90 days.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description
99.1

Press Release titled “FDA Approves World’s First Long-Term Implantable Continuous Glucose Monitoring System for Marketing in United States,” dated June 21, 2018.

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Senseonics Holdings, Inc.



By:
/s/ R. Don Elsey


R. Don Elsey


Chief Financial Officer


June 21, 2018


3